Abstract:Aims: Heart failure with reduced ejection fraction (HFrEF) is a leading cause of death worldwide; thus, therapeutic improvements are needed. In vivo preclinical models are essential to identify molecular drug targets for future therapies. Transverse aortic constriction (TAC) is a well-established model of HFrEF; however, highly experienced personnel are needed for the surgery, and several weeks of follow-up are necessary to develop HFrEF. To this end, we aimed (i) to develop an easy-to-perform mouse model of HFrEF by treating Balb/c mice with angiotensin-II (Ang-II) for 2 weeks by minipump and (ii) to compare its cardiac phenotype and transcriptome to the well-established TAC model of HFrEF in C57BL/6J mice. Methods: Mortality and gross pathological data, cardiac structural and functional characteristics assessed by echocardiography and immunohistochemistry and differential gene expression obtained by RNA-sequencing and gene-ontology analyses were used to characterize and compare the two models. To achieve statistical comparability between the two models, changes in treatment groups related to the corresponding control were compared (ΔTAC vs. ΔAng-II). Results: Compared with the well-established TAC model, chronic Ang-II treatment of Balb/c mice shares similarities in cardiac systolic functional decline (left ventricular ejection fraction: -57.25 ± 7.17% vs. -43.68 ± 5.31% in ΔTAC vs. ΔAng-II; P = 0.1794) but shows a lesser degree of left ventricular dilation (left ventricular end-systolic volume: 190.81 ± 44.13 vs. 57.37 ± 10.18 mL in ΔTAC vs. ΔAng-II; P = 0.0252) and hypertrophy (cell surface area: 58.44 ± 6.1 vs. 10.24 ± 2.87 μm2 in ΔTAC vs. ΔAng-II; P < 0.001); nevertheless, transcriptomic changes in the two HFrEF models show strong correlation (Spearman's r = 0.727; P < 0.001). In return, Ang-II treatment in Balb/c mice needs significantly less procedural time [38 min, interquartile range (IQR): 31-46 min in TAC vs. 6 min, IQR: 6-7 min in Ang-II; P < 0.001] and surgical expertise, is less of an object for peri-procedural mortality (15.8% in TAC vs. 0% in Ang-II; P = 0.105) and needs significantly shorter follow-up for developing HFrEF. Conclusions: Here, we demonstrate for the first time that chronic Ang-II treatment of Balb/c mice is also a relevant, reliable but significantly easier-to-perform preclinical model to identify novel pathomechanisms and targets in future HFrEF research.

The transverse aortic constriction heart failure animal model: a systematic review and meta-analysis

Pressure Overload-induced Cardiac Hypertrophy Varies According to Different Ligation Needle Sizes and Body Weights in Mice

A time-series minimally invasive transverse aortic constriction mouse model for pressure overload-induced cardiac remodeling and heart failure

Evaluation of the transverse aortic constriction model in ICR and C57BL/6J mice

Focus on bladder cancer

Unveiling reversibility and plasticity in cardiac hypertrophy: insights from a transverse aortic constriction-release model

Effect of an Acute Mechanical Stimulus on Aortic Structure in the Transverse Aortic Constriction Mouse Model

Surgical optimization and characterization of a minimally invasive aortic banding procedure to induce cardiac hypertrophy in mice

Structural and functional alterations in heart and skeletal muscle following severe TAC in mice: impact of moderate exercise training

Modified Protocol for A Mouse Heart Failure Model Using Minimally Invasive Transverse Aortic Constriction

O-ring-induced transverse aortic constriction (OTAC) is a new simple method to develop cardiac hypertrophy and heart failure in mice

Comparison of Heart Function Changes by Transverse Aortic Constriction in Different Strain Mice

Left Ventricular Response in the Transition from Hypertrophy to Failure Recapitulates Distinct Roles of Akt, Β-Arrestin-2, and CaMKII in Mice with Aortic Regurgitation

Gene Expression Profiling and Functional Analysis of Ventricular Tissues from Murine Transverse Aortic Constriction.

P098 CARDIAC REMODELING IN MICE TREATED WITH SODIUM OXALATE AND AORTIC STENOSIS

A New Minimally Invasive Method of Transverse Aortic Constriction in Mice.

Aortic remodeling after transverse aortic constriction in mice is attenuated with AT1 receptor blockade.

Comparison of mouse models of heart failure with reduced ejection fraction

Comparisons between novel minimally invasive and classic transverse aortic con-striction surgery model in mice

Experimental modelling of cardiac pressure overload hypertrophy: Modified technique for precise, reproducible, safe and easy aortic arch banding-debanding in mice

Evaluation of Bi-ventricular Coronary Flow Patterns Using High-Frequency Ultrasound in Mice with Transverse Aortic Constriction